These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 31288997)

  • 21. Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17.
    Petiot E; Proust A; Traversier A; Durous L; Dappozze F; Gras M; Guillard C; Balloul JM; Rosa-Calatrava M
    Vaccine; 2018 May; 36(22):3101-3111. PubMed ID: 28571695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-cell-density cultivations to increase MVA virus production.
    Vázquez-Ramírez D; Genzel Y; Jordan I; Sandig V; Reichl U
    Vaccine; 2018 May; 36(22):3124-3133. PubMed ID: 29433897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Formulation and production of a blood-free and chemically defined virus production media for VERO cells.
    Alfano R; Pennybaker A; Halfmann P; Huang CY
    Biotechnol Bioeng; 2020 Nov; 117(11):3277-3285. PubMed ID: 32648943
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increasing Vero viable cell densities for yellow fever virus production in stirred-tank bioreactors using serum-free medium.
    Mattos DA; Silva MV; Gaspar LP; Castilho LR
    Vaccine; 2015 Aug; 33(35):4288-91. PubMed ID: 25930117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation.
    Genzel Y; Dietzsch C; Rapp E; Schwarzer J; Reichl U
    Appl Microbiol Biotechnol; 2010 Sep; 88(2):461-75. PubMed ID: 20617311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influenza A virus production in a single-use orbital shaken bioreactor with ATF or TFF perfusion systems.
    Coronel J; Behrendt I; Bürgin T; Anderlei T; Sandig V; Reichl U; Genzel Y
    Vaccine; 2019 Nov; 37(47):7011-7018. PubMed ID: 31266669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human amniocyte-derived cells are a promising cell host for adenoviral vector production under serum-free conditions.
    Silva AC; Simão D; Küppers C; Lucas T; Sousa MF; Cruz P; Carrondo MJ; Kochanek S; Alves PM
    Biotechnol J; 2015 May; 10(5):760-71. PubMed ID: 25943527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perfusion Control for High Cell Density Cultivation and Viral Vaccine Production.
    Nikolay A; Bissinger T; Gränicher G; Wu Y; Genzel Y; Reichl U
    Methods Mol Biol; 2020; 2095():141-168. PubMed ID: 31858467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a high-yield live-virus vaccine production platform using a novel fixed-bed bioreactor.
    Berrie DM; Waters RC; Montoya C; Chatel A; Vela EM
    Vaccine; 2020 Apr; 38(20):3639-3645. PubMed ID: 32247568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells.
    Genzel Y; Vogel T; Buck J; Behrendt I; Ramirez DV; Schiedner G; Jordan I; Reichl U
    Vaccine; 2014 May; 32(24):2770-81. PubMed ID: 24583003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vero cells gain renal tubule markers in low-calcium and magnesium chemically defined media.
    Logan M; Rinas K; McConkey B; Aucoin MG
    Sci Rep; 2022 Apr; 12(1):6180. PubMed ID: 35418617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Production of a Foot-and-Mouth Disease Vaccine Antigen Using Suspension-Adapted BHK-21 Cells in a Bioreactor.
    Park S; Kim JY; Ryu KH; Kim AY; Kim J; Ko YJ; Lee EG
    Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34068378
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel process for production of hepatitis A virus in Vero cells grown on microcarriers in bioreactor.
    Sun MB; Jiang YJ; Li WD; Li PZ; Li GL; Jiang SD; Liao GY
    World J Gastroenterol; 2004 Sep; 10(17):2571-3. PubMed ID: 15300909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel animal-component-free medium for rabies virus production in Vero cells grown on Cytodex 1 microcarriers in a stirred bioreactor.
    Rourou S; van der Ark A; Majoul S; Trabelsi K; van der Velden T; Kallel H
    Appl Microbiol Biotechnol; 2009 Nov; 85(1):53-63. PubMed ID: 19521697
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development.
    Wu SC; Liu CC; Lian WC
    Vaccine; 2004 Sep; 22(29-30):3858-64. PubMed ID: 15364432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suspension culture of Vero cells for the production of adenovirus type 5.
    Lee DK; Park J; Seo DW
    Clin Exp Vaccine Res; 2020 Jan; 9(1):48-55. PubMed ID: 32095440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vero cell upstream bioprocess development for the production of viral vectors and vaccines.
    Kiesslich S; Kamen AA
    Biotechnol Adv; 2020 Nov; 44():107608. PubMed ID: 32768520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statistical optimization of influenza H1N1 production from batch cultures of suspension Vero cells (sVero).
    Paillet C; Forno G; Soldano N; Kratje R; Etcheverrigaray M
    Vaccine; 2011 Sep; 29(41):7212-7. PubMed ID: 21756959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system.
    Vázquez-Ramírez D; Jordan I; Sandig V; Genzel Y; Reichl U
    Appl Microbiol Biotechnol; 2019 Apr; 103(7):3025-3035. PubMed ID: 30796494
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Semi-perfusion cultures of suspension MDCK cells enable high cell concentrations and efficient influenza A virus production.
    Bissinger T; Fritsch J; Mihut A; Wu Y; Liu X; Genzel Y; Tan WS; Reichl U
    Vaccine; 2019 Nov; 37(47):7003-7010. PubMed ID: 31047676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.